You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫療集團(08225.HK)計劃幫助300個醫院建立悦戒門診、500個藥店建立戒煙藥專區
格隆匯 06-03 07:39

格隆匯6月3日丨中國醫療集團(08225.HK)公佈,2021年5月31日世界無煙日·中國悦戒節,中國醫療集團成功組織承諾戒煙線上誓師大會,悦戒(煙)軍團小程式發佈,中國醫療控煙大醫生評選和悦戒真實世界臨牀研究啟動。

煙草成癮疾病是全球最流行致命的慢性腦疾病,中國三億多人患煙草疾病,七億多二手煙受害被傳染致命疾病,吸煙導致癌症、卒中、心臟、呼吸、糖尿病和生殖等多種疾病。吸煙患者更容易患新冠肺炎死亡率也比相同條件下非吸煙患者高。

中國煙草工業市場利税達1.1萬億,戒煙市場也高達三千億。集團下屬的悦戒煙成癮疾病中心是目前國內最大慢病領域的領先機構之一,這次將對包括悦亭等戒煙藥展開對煙草成癮疾病與癌症、卒中、心血管、哮喘和慢阻肺等多疾病治療觀察展開真實世界大資料研究。電子煙“悦刻”一度創造新亞洲首富,近期電子煙被國家進一步限制使用。此次集團組織包括早年著名院士鍾南山、胡大一專家領導研究機構參加臨牀研究的戒煙藥“悦亭”的進一步真實世界臨牀研究,和數位化戒煙平台“悦戒軍團”,將會更加有效幫助3億吸煙患者的康復。

集團計劃幫助300個醫院建立悦戒門診、500個藥店建立戒煙藥專區。集團認為由於集團在控煙巨大商業市場中的領先地位,以臨牀研究,大資料和數位化推動的商業活動將會為集團獲取可觀的經濟效益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account